Shanghai Junshi Biosciences Future Growth
Future criteria checks 2/6
Shanghai Junshi Biosciences is forecast to grow earnings and revenue by 26.2% and 22.9% per annum respectively. EPS is expected to grow by 28.4% per annum. Return on equity is forecast to be -39.2% in 3 years.
Key information
26.2%
Earnings growth rate
28.4%
EPS growth rate
| Biotechs earnings growth | 35.6% |
| Revenue growth rate | 22.9% |
| Future return on equity | -39.2% |
| Analyst coverage | Low |
| Last updated | 11 Jun 2024 |
Recent future growth updates
Recent updates
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth
May 06
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Mar 22Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%
Jan 26Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Dec 17Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?
Nov 20Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?
Sep 05Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
May 22Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate
May 01A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Jan 16Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 03Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Oct 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,963 | -1,003 | -1,395 | -1,021 | 2 |
| 12/31/2025 | 2,451 | -1,194 | -1,661 | -1,162 | 3 |
| 12/31/2024 | 1,787 | -1,602 | -2,021 | -1,514 | 3 |
| 3/31/2024 | 1,628 | -2,023 | -2,581 | -1,661 | N/A |
| 12/31/2023 | 1,503 | -2,283 | -2,838 | -2,005 | N/A |
| 9/30/2023 | 1,222 | -2,200 | -3,037 | -2,323 | N/A |
| 6/30/2023 | 1,177 | -2,473 | -2,988 | -2,544 | N/A |
| 3/31/2023 | 1,079 | -2,535 | -3,489 | -3,067 | N/A |
| 12/31/2022 | 1,453 | -2,388 | -2,170 | -1,776 | N/A |
| 9/30/2022 | 2,525 | -1,924 | -1,708 | -1,182 | N/A |
| 6/30/2022 | 2,856 | -1,643 | -1,663 | -1,109 | N/A |
| 3/31/2022 | 3,039 | -1,495 | -1,207 | -434 | N/A |
| 12/31/2021 | 4,025 | -721 | -1,507 | -605 | N/A |
| 9/30/2021 | 3,302 | -945 | -1,769 | -902 | N/A |
| 6/30/2021 | 3,134 | -1,060 | -1,735 | -892 | N/A |
| 3/31/2021 | 3,038 | -1,062 | -1,398 | -703 | N/A |
| 12/31/2020 | 1,595 | -1,669 | -2,037 | -1,456 | N/A |
| 9/30/2020 | 1,259 | -1,418 | -1,945 | -1,365 | N/A |
| 6/30/2020 | 1,041 | -1,056 | -1,699 | -1,032 | N/A |
| 3/31/2020 | 868 | -600 | -1,876 | -1,120 | N/A |
| 12/31/2019 | 775 | -747 | -2,042 | -1,179 | N/A |
| 9/30/2019 | 528 | -732 | -1,927 | -1,092 | N/A |
| 6/30/2019 | 310 | -735 | -1,704 | -913 | N/A |
| 3/31/2019 | 79 | -992 | -1,555 | -824 | N/A |
| 12/31/2018 | 1 | -717 | -1,060 | -511 | N/A |
| 9/30/2018 | N/A | -516 | -877 | -387 | N/A |
| 6/30/2018 | N/A | -439 | -775 | -443 | N/A |
| 3/31/2018 | 0 | -347 | -603 | -364 | N/A |
| 12/31/2017 | 1 | -321 | N/A | -347 | N/A |
| 9/30/2017 | 9 | -279 | N/A | -348 | N/A |
| 6/30/2017 | 5 | -246 | N/A | -275 | N/A |
| 3/31/2017 | 9 | -191 | N/A | -243 | N/A |
| 12/31/2016 | 4 | -131 | N/A | -185 | N/A |
| 9/30/2016 | 4 | -109 | N/A | -169 | N/A |
| 6/30/2016 | 2 | -83 | N/A | -139 | N/A |
| 3/31/2016 | 2 | -71 | N/A | -110 | N/A |
| 12/31/2015 | 3 | -58 | N/A | -82 | N/A |
| 9/30/2015 | 5 | -43 | N/A | -66 | N/A |
| 6/30/2015 | 7 | -27 | N/A | -50 | N/A |
| 3/31/2015 | 6 | -26 | N/A | -45 | N/A |
| 12/31/2014 | 6 | -25 | N/A | -39 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1877 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1877 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1877 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1877's revenue (22.9% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 1877's revenue (22.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1877 is forecast to be unprofitable in 3 years.